<DOC>
	<DOCNO>NCT02218073</DOCNO>
	<brief_summary>The purpose study evaluate absolute bioavailability ( extent drug substance become available body ) JNJ-42756493 follow single 10 milligram ( mg ) dose oral solution administer combination single intravenous administration microdose ( 100 microgram [ mcg ] ) JNJ-61818549 evaluate relative bioavailability 10 mg JNJ-42756493 follow oral solution ( reference ) tablet ( test ) formulation crossover ( method use switch subject one study group another clinical trial ) design healthy participant .</brief_summary>
	<brief_title>Pharmacokinetic Study JNJ-42756493 Healthy Participants</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( people know identity intervention ) , 2-way crossover , single-dose , single-center , Phase 1 study oral JNJ-42756493 healthy participant . The duration study approximately 36-63 day : 2-20 day Screening , two 7 day open-label treatment period , 12-14 day washout 12-14-day follow-up ( Day 13-15 period 2 ) . All participant randomly assign 1 2 treatment sequence . In Treatment Sequence AB : JNJ-42756493 10 mg tablet formulation administer Day 1 Period 1 100 mcg JNJ-61818549 administer intravenously 2 hour intake 10 mg JNJ-42756493 oral solution Day 1 Period 2 . In Treatment Sequence BA : 100 mcg JNJ-61818549 administer intravenously intake 10 mg JNJ-42756493 oral solution Day 1 Period 1 10 mg JNJ-42756493 tablet formulation administer Day 1 Period 2 . A minimum 12 day washout required treatment period . Participants primarily analyze pharmacokinetics ( study way drug enters leave blood tissue time ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Received thorough explanation optional pharmacogenomic research component study offer opportunity participate sign separate pharmacogenomic inform consent document If woman , must postmenopausal ( spontaneous menses least 2 year ) , surgically sterile If woman , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screen Body mass index ( BMI ) ( weight kilogram [ kg ] / height square meter [ m^2 ] 18 30 kg/m^2 ( inclusive ) , body weight less 50 kg Nonsmoker least 6 month enter study History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , metabolic bone disease ( osteoporosis ) , infection , illness investigator considers exclude subject could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry urinalysis screen predose Day 2 ( urinalysis ) Day 1 treatment Period deem appropriate investigator . Retesting abnormal lab value may lead exclusion allow Clinically significant abnormal physical examination , vital sign 12lead electrocardiogram ( ECG ) screen Day 1 treatment Periods deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol hormonal replacement therapy within 14 day first dose study drug schedule History , reason believe participant history drug alcohol abuse within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42756493</keyword>
	<keyword>JNJ-61818549</keyword>
	<keyword>Isotope</keyword>
</DOC>